Literature DB >> 16263140

Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix.

Tobias Engl1, Borna Relja, Christa Blumenberg, Iris Müller, Eva M Ringel, Wolf-Dietrich Beecken, Dietger Jonas, Roman A Blaheta.   

Abstract

Though chemokines of the CXC family are thought to play key roles in neoplastic transformation and tumor invasion, information about CXC chemokines in prostate cancer is sparse. To evaluate the involvement of CXC chemokines in prostate cancer, we analyzed the CXC coding mRNA of both chemokine ligands (CXCL) and chemokine receptors (CXCR), using the prostate carcinoma cell lines PC-3, DU-145 and LNCaP. CXCR proteins were further evaluated by Western blot, CXCR surface expression by flow cytometry and confocal microscopy. The expression pattern was correlated to adherence of the tumor cells to an endothelial cell monolayer or to extracellular matrix components. Based on growth and adhesion capacity, PC-3 and DU-145 were identified to be highly aggressive tumor cells (PC-3>DU-145), whereas LNCaP belonged to the low aggressive phenotype. CXCL1, CXCL3, CXCL5 and CXCL6 mRNA, chemokines with pro-angiogenic activity, were strongly expressed in DU-145 and PC-3, but not in LNCaP. CXCR3 and CXCR4 surface level differed in the following order: LNCaP>DU-145>PC-3. The differentiation factor, fatty acid valproic acid, induced intracellular CXCR accumulation. Therefore, prostate tumor malignancy might be accompanied by enhanced synthesis of angiogenesis stimulating CXC chemokines. Further, shifting CXCR3 and CXCR4 from the cell surface to the cytoplasm might activate pro-tumoral signalling events and indicate progression from a low to a highly aggressive phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16263140     DOI: 10.1016/j.lfs.2005.08.019

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  35 in total

1.  Overexpression of CXCL3 can enhance the oncogenic potential of prostate cancer.

Authors:  Shi-Liang Gui; Li-Chen Teng; Shu-Qiu Wang; Shuang Liu; Ying-Li Lin; Xiao-Lian Zhao; Lei Liu; Hong-Yu Sui; Yang Yang; Li-Chun Liang; Mo-Lin Wang; Xin-Yi Li; Yu Cao; Feng-Ying Li; Wei-Qun Wang
Journal:  Int Urol Nephrol       Date:  2016-02-02       Impact factor: 2.370

Review 2.  CXCR3 in carcinoma progression.

Authors:  Bo Ma; Ahmad Khazali; Alan Wells
Journal:  Histol Histopathol       Date:  2015-02-09       Impact factor: 2.303

3.  Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms.

Authors:  Mario Menschikowski; Albert Hagelgans; Eugene Gussakovsky; Heike Kostka; Elena L Paley; Gabriele Siegert
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

4.  Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion.

Authors:  Shailesh Singh; Rajesh Singh; Praveen K Sharma; Udai P Singh; Shesh N Rai; Leland W K Chung; Carlton R Cooper; Kristian R Novakovic; William E Grizzle; James W Lillard
Journal:  Cancer Lett       Date:  2009-04-17       Impact factor: 8.679

5.  Chemokine receptor CXCR3 promotes growth of glioma.

Authors:  Che Liu; Defang Luo; Brent A Reynolds; Geeta Meher; Alan R Katritzky; Bao Lu; Craig J Gerard; Cyrus P Bhadha; Jeffrey K Harrison
Journal:  Carcinogenesis       Date:  2010-11-03       Impact factor: 4.944

6.  A screen for short-range paracrine interactions.

Authors:  K H Spencer; M Y Kim; C C W Hughes; E E Hui
Journal:  Integr Biol (Camb)       Date:  2014-02-13       Impact factor: 2.192

Review 7.  The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis.

Authors:  S Gelmini; M Mangoni; M Serio; P Romagnani; E Lazzeri
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

8.  Gene expression down-regulation in CD90+ prostate tumor-associated stromal cells involves potential organ-specific genes.

Authors:  Laura E Pascal; Young Ah Goo; Ricardo Zn Vêncio; Laura S Page; Amber A Chambers; Emily S Liebeskind; Thomas K Takayama; Lawrence D True; Alvin Y Liu
Journal:  BMC Cancer       Date:  2009-09-08       Impact factor: 4.430

9.  MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.

Authors:  Paul Cao; Zhiyong Deng; Meimei Wan; Weiwei Huang; Scott D Cramer; Jianfeng Xu; Ming Lei; Guangchao Sui
Journal:  Mol Cancer       Date:  2010-05-17       Impact factor: 27.401

10.  Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines.

Authors:  Shailesh Singh; Rajesh Singh; Udai P Singh; Shesh N Rai; Kristian R Novakovic; Leland W K Chung; Peter J Didier; William E Grizzle; James W Lillard
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.